Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07231419

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Conditions: Diabetic Peripheral Neuropathic Pain

Sex: All

Ages: 18 Years – 80 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 734

Sponsor: Vertex Pharmaceuticals Incorporated

Location: Central Research Associates, LLC Birmingham Alabama

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).

Eligibility Criteria

Key Inclusion Criteria: * Body weight greater than or equal to (≥)45 kilogram (kg) * Body mass index (BMI) ≥18 to less than (\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07231419). StuddyBuddy aggregates publicly available trial information.